厄贝沙坦联合左旋氨氯地平或吲达帕胺对原发性高血压患者血压变异性的影响

Effects of irbesartan combined with levamlodipine or indapamide regimen on blood pressure variation in patients with primary hypertensive

研究表明,血压变异性（BPV）与靶器官损害呈正相关,是心脑血管疾病发病风险的预测因素[1]。2007年ESC/ESH高血压指南指出,不同种类的降压药物联合应用是降压治疗的重要策略[2]。本研究旨在探讨厄贝沙坦联合左旋氨氯地平或吲达帕胺对原发性高血压患者BPV的影响,为原发性高血压的临床治疗提供参考。

Summary A total of 83 patients with primary hypertension were randomized into levamlodipine group （irbe sartan＋ levamlodipine） and indapamide group （irbesartan ＋ indapamide）. 24-hour ambulatory blood pressure monitoring was performed at baseline, 12 and 24 weeks after treatment. At 12 and 24 weeks, Z4-hours DBPV and daytime SBPV were lower in levamlodipine group than those in indapamide group. At 24 weeks, morning SBP, 24-hours DBPV and SBPV were significantly lower in levamlodipine group than those in indapamide group. Irbesartan in combination with levamlodipine or indapamide can both effectively reduce BPV in patients with primary hypertensive,but the former regimen is more suitable.